On January 12, the topic of "the era of 10,000 yuan of dental implants is coming to an end" appeared on the hot search
.
What's going on? In the future, there is no need to "look at the teeth and sigh"?
The price reduction of dental implants is closely related
to the centralized procurement policy.
On January 11, according to the National Health Insurance Administration, the centralized procurement of oral implant system was opened in Sichuan, resulting in the results of the proposed selection
.
Specifically, there are 55 enterprises participating in this collective procurement bidding, of which 39 are to be selected, with a winning rate of 71%.
In terms of price, the price range of the selected products is about 600 yuan to 1850 yuan, with an average decrease of 55%.
According to reports, this collection gathered the demand of nearly 18,000 medical institutions across the country, reaching 2.
87 million implant systems, accounting for about 72% of the annual number of dental implants in China (4 million), and is expected to save about 4 billion yuan in patient costs every year
.
The 39 enterprises to be selected this time include domestic enterprises such as Weihai Weigao and Changzhou Baikante, as well as some imported brands, and the price of some imported brands has even dropped to more than 100 yuan
.
Among them, the Swiss brand Straumann, the American brand Densberg, and the Swedish brand Nobco implant system decreased from the original median purchase price of 5000 yuan to about 1850 yuan, and the Korean brand Aoyutai and Dentten implant system decreased from the original median purchase price of about 1500 yuan to about
770 yuan.
At the same time, the selected products are also relatively rich, including two kinds of implants with better material performance and higher clinical recognition of grade IV pure titanium and titanium alloy, and covering other consumable parts of oral implants, which can meet most clinical use needs
.
Relevant people from the National Health Insurance Administration said that the cost of oral implants is roughly divided into three parts
: implants, crowns and medical services.
This collective procurement is aimed at the price adjustment
of implants.
It is understood that in the past, the average cost of a dental implant ranged from 6,000 yuan to 20,000 yuan, and many patients paid a lot of pressure, could not afford to implant teeth, and it was difficult to implant teeth
.
After this collection, it is expected that the overall cost of implanting a tooth (including medical services, implants and crowns) will be reduced by about
half.
In the next step, the medical insurance department will make preparations before the implementation of the results of centralized procurement, and in the near future, it will also carry out bidding and listing of crown consumables used in the process of dental implants, and simultaneously implement the whole process of price regulation of oral implant medical services, so that the three main cost components of dental implant services will be reduced
simultaneously.
Through the concerted efforts of a number of measures, it is expected that from late March to mid-April 2023, the results of comprehensive management of dental implant costs will be implemented, and patients will fully enjoy the reduced dental implant services
.
For the impact that this collection will bring, the industry estimates that the number of domestic dental implants will increase significantly on the existing basis, and the oral problems of a large number of patients will be significantly improved
by this collection.
For private medical institutions, as the main providers of oral medical services, enterprises entering centralized procurement are expected to exchange price for volume, which is conducive to improving the reputation of enterprises, expanding social influence, increasing patient recognition, and reflecting social responsibility
.
However, in the secondary market, the stock prices of related companies in the A-share market reacted mediocre
to the results of this dental implant collection.
At the opening on January 12, Tongce Medical, Guocera Materials, Meiya Optoelectronics, Zhenghai Biotechnology, etc.
all fell
slightly.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
